Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients

Journal of Endocrinological Investigation

Volumn 29, Issue 10, 2006, Pages 858-862

  Gursoy, Alptekin ^a   Erdogan, M F ^a   Erdogan, G ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Age of onset; Lymph node involvement; Medullary thyroid carcinoma; Polymorphisms; RET proto oncogene; Sporadic

Indexed keywords

GLYCINE; LEUCINE; PROTEIN RET; SERINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MALE; NUCLEOTIDE SEQUENCE; ONSET AGE; POLYMERASE CHAIN REACTION; PROTO ONCOGENE; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TURKEY (REPUBLIC);

EID: 33846556213     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03349187     Document Type: Article

References (21)

1. Raue F, Frank-Raue K, Grauer A. Multiple endocrine neoplasia type 2. Clinical features and screening. Endocrinol Metab Clin North Am 1994, 23: 137-56.
2. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2: 851-6.
3. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363: 458-60.
4. Eng C, Clayton D, Schuffenecker I, et al. The relation between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplaia type 2: international RET Mutation Consortium analysis. JAMA 1996, 276: 1575-9.
5. Edery P, Attie T, Mulligan LM, et al. A novel polymorphism in the coding sequence of the human RET proto-oncogene. Hum Genet 1994, 94: 579-80.
6. Bugalho MJ, Cote GJ, Khorana S, Schultz PN, Gagel RF. Identification of a polymorphism in exon 11 of the RET proto-oncogene. Hum Mol Genet 1994, 3: 2263.
7. Baumgartner-Parzer SM, Lang R, Wagner L, et al. Polymorphisms in exon 13 and intron 14 of the RET proto-oncogene: Genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab 2005, 90: 6232-6.
8. Cebrian A, Lesueur F, Martin S, et al. Polymorphisms in the initiators of RET signalling pathway and susceptibility to sporadic Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 2005, 90: 6268-74.
9. Robledo M, Gil L, Pollan M, et al. Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res 2003, 63: 1814-7.
10. Elisei R, Cosci B, Romei C, et al. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 2005, 89: 3579-84.
11. Gimm O, Neuberg DS, Marsh DJ, et al. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 1999, 18: 1369-73.
12. Ruiz A, Antinolo G, Fernandez RM, Eng C, Marcos I, Borrego S. Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clin Endocrinol (Oxf) 2001, 55: 399-402.
13. Wiench M, Wloch J, Wygoda Z, et al. RET polymorphisms in codons 769 and 836 are not associated with predisposition to medullary thyroid carcinoma. Cancer Detect Prev 2004, 28: 231-6.
14. Wohllk GN, Soto CE, Bravo AM, Becker CP. G691S, L769L and S836S ret proto-oncogene polymorphisms are not associated with higher risk to sporadic medullary thyroid carcinoma in Chilean patients. Rev Med Chil 2005, 133: 397-402.
15. Berard I, Kraimps JL, Savagner F, et al. Germline-sequence variants S836S and L769L in the RE arranged during Transfection (RET) proto-oncogene are not associated with predisposition to sporadic medullary carcinoma in the French population. Clin Genet 2004, 65: 150-2.
16. Vineis P. Individual susceptibility to carcinogens. Oncogene 2004, 23: 6477-83.
17. Costa P, Domingues R, Sobrinho LG, Joao Bugalho M. RET polymorphisms and sporadic medullary thyroid carcinoma in a Portuguese population. Endocrine 2005, 27: 239-43.
18. Erdogan MF, Gursoy A, Ozgen G, et al. Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study. J Endocrinol Invest 2005, 28: 806-9.
19. Magalhaes PK, de Castro M, Elias LL, Soares EG, Maciel LM. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma. Thyroid 2004, 14: 848-52.
20. Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 2002, 963: 116-21.
21. Kurokawa K, Kawai K, Hashimoto M, Ito Y, Takahashi M. Cell signalling and gene expression mediated by RET tyrosine kinase. J Intern Med 2003, 253: 627-33.